Since this seminal work, studies have turned largely to inducing CD8 T cell responses, and several MHC I-restricted epitopes from gp100 [45], TRP-2 [46], tyrosinase [47], and TRP-1 [48] have since been employed as targets of melanoma vaccines and cellular therapies. Here, TYRP1 is linked to melanoma.